LH - LH ラボラトリ―・コ―プ・オブ・アメリカ・ホ―ルディングス （）

Related Stocks: LH , KKR , PFG , SHEL , CTVA ,

Related Stocks: LPLA , LH , BECN , FLEX , QSR ,

DENVER--(BUSINESS WIRE)--VieCure today announced a new collaboration with Labcorp to provide clinicians greater access to precision oncology decision support. This strategic collaboration will support patient-specific treatment plans by integrating Labcorp’s precision medicine testing solutions with VieCure’s clinical decision support tool, helping community cancer care providers advance health equity and increase precision diagnostic test utilization for cancer patients, including those living

Labcorp has a long growth runway as its efficient scale makes it appealing for hospitals to outsource this essential function. Read more here.

BURLINGTON, N.C. --(BUSINESS WIRE)--Jan. 18, 2023-- Labcorp (NYSE: LH), a leading global life sciences company, will release its financial results for the fourth quarter and full year 2022 before the market opens on Thursday, Feb. 16, 2023 . The company will host a conference call and webcast

WASHINGTON (dpa-AFX) - Labcorp (LH) announced that Thomas Pike will join the company as president and chief executive officer of its Drug Development Clinical Development business unit on Jan. 9, …

BURLINGTON, N.C. --(BUSINESS WIRE)--Jan. 3, 2023-- Labcorp (NYSE: LH), a leading global life sciences company, today announced that members of the executive management team will participate in a fireside chat at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 10 at 4:30 p.m.

Walt Disney tops the list of investor Jon Boyar’s selections, The others are Liberty Braves Group, Uber Technologies, Markel, Watsco, and LabCorp.

In September 2021, Syneos Health entered into a strategic collaboration with Ride Health to offer non-emergency medical transportation (NEMT) for clinical trial participants. Northbrook, IL 60062 -- ( SBWIRE ) -- 12/15/2022 -- The Global Clinical Trials Market by Phase (Phase I, II, III), Service Type (Site Identification, Laboratory Services, Decentralized Clinical Trial), Therapy Area (Oncology, Infectious Disease), and Application (Vaccines, Cell & Gene Therapy) - Global Forecast to 2026" published by MarketsandMarkets, the clinical trials market is projected to reach USD 52.0 billion by 2026 from USD 38.7 billion in 2021, at a CAGR of 6.1% during the forecast period. Factors such as growing R&D expenditure, increasing outsourcing of R&D activities, and the rising number of clinical trials worldwide are driving the growth of the global clinical trials market. The growing biosimilars and biologics market, rising demand for specialized testing services, and emerging Asian markets also offer significant growth opportunities for players operating in the market.

Laboratory Corporation of Ameri with ticker code (LH) have now 13 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The target price ranges between 315 and 250 with a mean TP of 276.54. Given that the stocks previous close was at 231.13 this would indicate that there is a potential upside of 19.6%. The 50 day moving average now sits at 227.24 and the 200 moving average now moves to 241.88. The market cap for the company is $20,433m. Find out more information at: https://www.labcorp.com [stock_market_widget type="chart" template="basic" color="green" assets="LH" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $24,447m based on the market concensus. Laboratory Corporation of America Holdings operates as a global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD).

Walt Disney tops the list of investor Jon Boyar’s selections, The others are Liberty Braves Group, Uber Technologies, Markel, Watsco, and LabCorp.

In September 2021, Syneos Health entered into a strategic collaboration with Ride Health to offer non-emergency medical transportation (NEMT) for clinical trial participants. Northbrook, IL 60062 -- ( SBWIRE ) -- 12/15/2022 -- The Global Clinical Trials Market by Phase (Phase I, II, III), Service Type (Site Identification, Laboratory Services, Decentralized Clinical Trial), Therapy Area (Oncology, Infectious Disease), and Application (Vaccines, Cell & Gene Therapy) - Global Forecast to 2026" published by MarketsandMarkets, the clinical trials market is projected to reach USD 52.0 billion by 2026 from USD 38.7 billion in 2021, at a CAGR of 6.1% during the forecast period. Factors such as growing R&D expenditure, increasing outsourcing of R&D activities, and the rising number of clinical trials worldwide are driving the growth of the global clinical trials market. The growing biosimilars and biologics market, rising demand for specialized testing services, and emerging Asian markets also offer significant growth opportunities for players operating in the market.

Laboratory Corporation of Ameri with ticker code (LH) have now 13 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The target price ranges between 315 and 250 with a mean TP of 276.54. Given that the stocks previous close was at 231.13 this would indicate that there is a potential upside of 19.6%. The 50 day moving average now sits at 227.24 and the 200 moving average now moves to 241.88. The market cap for the company is $20,433m. Find out more information at: https://www.labcorp.com [stock_market_widget type="chart" template="basic" color="green" assets="LH" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $24,447m based on the market concensus. Laboratory Corporation of America Holdings operates as a global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD).

Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has begun operations at a new, larger anatomic pathology and histology (APH) laboratory in Los Angeles, expanding the company’s global central laboratory capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221208005956/en/ Photo

Charles River Laboratories and Labcorp shares fall on potential NHP supply issues